Reversal of Stress-Induced Social Interaction Deficits by Buprenorphine
- PMID: 29020387
- PMCID: PMC5793841
- DOI: 10.1093/ijnp/pyx079
Reversal of Stress-Induced Social Interaction Deficits by Buprenorphine
Abstract
Background: Patients with post-traumatic stress disorder frequently report persistent problems with social interactions, emerging after a traumatic experience. Chronic social defeat stress is a widely used rodent model of stress that produces robust and sustained social avoidance behavior. The avoidance of other rodents can be reversed by 28 days of treatment with selective serotonin reuptake inhibitors, the only pharmaceutical class approved by the U.S. Food and Drug Administration for treating post-traumatic stress disorder. In this study, the sensitivity of social interaction deficits evoked by 10 days of chronic social defeat stress to prospective treatments for post-traumatic stress disorder was examined.
Methods: The effects of acute and repeated treatment with a low dose of buprenorphine (0.25 mg/kg/d) on social interaction deficits in male C57BL/6 mice by chronic social defeat stress were studied. Another cohort of mice was used to determine the effects of the selective serotonin reuptake inhibitor fluoxetine (10 mg/kg/d), the NMDA antagonist ketamine (10 mg/kg/d), and the selective kappa opioid receptor antagonist CERC-501 (1 mg/kg/d). Changes in mRNA expression of Oprm1 and Oprk1 were assessed in a separate cohort.
Results: Buprenorphine significantly reversed social interaction deficits produced by chronic social defeat stress following 7 days of administration, but not after acute injection. Treatment with fluoxetine for 7 days, but not 24 hours, also reinstated social interaction behavior in mice that were susceptible to chronic social defeat. In contrast, CERC-501 and ketamine failed to reverse social avoidance. Gene expression analysis found: (1) Oprm1 mRNA expression was reduced in the hippocampus and increased in the frontal cortex of susceptible mice and (2) Oprk1 mRNA expression was reduced in the amygdala and increased in the frontal cortex of susceptible mice compared to non-stressed controls and stress-resilient mice.
Conclusions: Short-term treatment with buprenorphine and fluoxetine normalized social interaction after chronic social defeat stress. In concert with the changes in opioid receptor expression produced by chronic social defeat stress, we speculate that buprenorphine's efficacy in this model of post-traumatic stress disorder may be associated with the ability of this compound to engage multiple opioid receptors.
Keywords: CERC-501; PTSD; buprenorphine; chronic social defeat stress; fluoxetine; ketamine; social interaction.
Published by Oxford University Press on behalf of CINP 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Figures
Similar articles
-
Antidepressant-like actions of the mGlu2/3 receptor antagonist TP0178894 in the chronic social defeat stress model: Comparison with escitalopram.Pharmacol Biochem Behav. 2022 Jan;212:173316. doi: 10.1016/j.pbb.2021.173316. Epub 2021 Dec 27. Pharmacol Biochem Behav. 2022. PMID: 34968554
-
5-Hydroxytryptamine-Independent Antidepressant Actions of (R)-Ketamine in a Chronic Social Defeat Stress Model.Int J Neuropsychopharmacol. 2018 Feb 1;21(2):157-163. doi: 10.1093/ijnp/pyx100. Int J Neuropsychopharmacol. 2018. PMID: 29155989 Free PMC article.
-
Amygdala dynorphin/κ opioid receptor system modulates depressive-like behavior in mice following chronic social defeat stress.Acta Pharmacol Sin. 2022 Mar;43(3):577-587. doi: 10.1038/s41401-021-00677-6. Epub 2021 May 25. Acta Pharmacol Sin. 2022. PMID: 34035484 Free PMC article.
-
In a mouse model relevant for post-traumatic stress disorder, selective brain steroidogenic stimulants (SBSS) improve behavioral deficits by normalizing allopregnanolone biosynthesis.Behav Pharmacol. 2010 Sep;21(5-6):438-50. doi: 10.1097/FBP.0b013e32833d8ba0. Behav Pharmacol. 2010. PMID: 20716970 Free PMC article. Review.
-
Up-regulation of neurosteroid biosynthesis as a pharmacological strategy to improve behavioural deficits in a putative mouse model of post-traumatic stress disorder.J Neuroendocrinol. 2012 Jan;24(1):102-16. doi: 10.1111/j.1365-2826.2011.02234.x. J Neuroendocrinol. 2012. PMID: 21981145 Free PMC article. Review.
Cited by
-
Buprenorphine as a Treatment for Major Depression and Opioid Use Disorder.Adv Drug Alcohol Res. 2022;2:10254. doi: 10.3389/adar.2022.10254. Epub 2022 Feb 21. Adv Drug Alcohol Res. 2022. PMID: 36177442 Free PMC article.
-
Attachment Insecurity in Rats Subjected to Maternal Separation and Early Weaning: Sex Differences.Front Behav Neurosci. 2021 Apr 7;15:637678. doi: 10.3389/fnbeh.2021.637678. eCollection 2021. Front Behav Neurosci. 2021. PMID: 33897386 Free PMC article.
-
Ketamine's rapid antidepressant effects are mediated by Ca2+-permeable AMPA receptors.Elife. 2023 Jun 26;12:e86022. doi: 10.7554/eLife.86022. Elife. 2023. PMID: 37358072 Free PMC article.
-
The Role of Dynorphin and the Kappa Opioid Receptor in Schizophrenia and Major Depressive Disorder: A Translational Approach.Handb Exp Pharmacol. 2022;271:525-546. doi: 10.1007/164_2020_396. Handb Exp Pharmacol. 2022. PMID: 33459877 Review.
-
Reduction of stress responses in honey bees by synthetic ligands targeting an allatostatin receptor.Sci Rep. 2022 Oct 6;12(1):16760. doi: 10.1038/s41598-022-20978-y. Sci Rep. 2022. PMID: 36202961 Free PMC article.
References
-
- Aan Het Rot M, Collins KA, Murrough JW, Perez AM, Reich DL, Charney DS, Mathew SJ(2010)Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry 67:139–145. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
